Endocrine Abstracts

Since the emergence of the Covid-19 pandemic in 2019, a massive vaccination campaign has been undertaken around the world, and SARS-CoV-2 vaccines-induced thyroid diseases became more frequently described in the literature. Subacute thyroiditis is reported in 52 patients, mean age 45.5±1.8 years, mainly in women (n = 39), after the first (62%) or the second (38%) dose of mRNA (60%), inactivated whole-virus (25%) and adenoviral-vectored (13.5%) vaccines. The mean ti...

SARS-CoV-2 vaccination campaigns document a satisfactory high profile of protection against Covid-19 infection, but auto-immune/inflammatory diseases have been reported following Covid-19 vaccines. A 65-year-old woman reported two days following her first dose of the BNT162b2 mRNA vaccine tearing, eye irritation, conjunctival redness, peri-orbital swelling, spontaneous hematoma of the right lower eyelid, right greater than left proptosis, with a spontaneous improvement of symp...

Introduction: Primary SMSa treatment can be associated with hormonal remission and tumor shrinkage in patients with GH-secreting pituitary adenomas. In the 2014 Endocrine Society guideline for Acromegaly, there is no specific mention of MRI follow-up during long-term SMSa treatment. The aim of this study was to evaluate any change of GH-secreting adenoma size during primary SMSa treatment and whether regular MRI follow-up was necessary in acromegalic patients treated with firs...

Thyroid-associated orbitopathy (TAO) is a classic and sometimes severe complication of autoimmune process associated with thyroid diseases, more common in Graves’ disease. Due to its functional impairment and disfiguring clinical presentation, TAO affects the quality of life of patients. Few studies have examined the importance of this impact in these patients. The main objective of this retrospective study is to determine if there is a correlation between the deteriorati...

Objectives: First-generation SMSa are the medical treatment of choice in the management of acromegaly, mainly as adjuvant treatment of pituitary surgery when normal IGF-1 is not obtained or as primary treatment in selected patients. The main objective of this study is to evaluate regular pituitary MRI follow-up of acromegalic patients treated with SMSa as adjuvant treatment of pituitary surgery. The secondary objective is to compare the anti-tumoral effect of SMSa in post-oper...

Introduction: Abnormalities of glycoregulation are frequent in acromegaly (15-38%) secondary to insulin resistance related to GH/IGF-1 hyper-secretion. The frequency of gestational diabetes (GD) in women with acromegaly was reported in the French multicenter study (JCEM, 2010, 95, 4680) as increased mainly in the absence of pre-gestational control of GH/IGF-1 hyper-secretion. The aim of this study was to evaluate the frequency of GD in a cohort of acromegalic women, and compar...

Objective: To compare the performances of the coronal contrast-enhanced T1-weighted (ceT1-w) and T2-weighted (T2-w) sequences, for the diagnosis of progression during the MRI follow-up of NFPAs.Materials and methods: 106 patients who had at least two MRIs for the follow-up of NFPA were retrospectively included. The largest diameter of the adenomas was measured on coronal ceT1-w and separately on T2-w sequences for all the MRIs of the follow-up, and by 2 ...

Introduction: Acromegaly is associated with multiple comorbidities and excess mortality. However, disease burden is reduced by maintaining IGF-1 (and/or GH) levels under safe levels. First generation long-acting SMSa, administered at monthly intervals, represent the first line medical treatment. According to guidelines, its efficacy is evaluated through IGF-I measurements. However, there are no data indicating the optimal time for measuring IGF-I levels after the SMSa injectio...

Background: Hyperphagia leading to craniopharyngioma-related obesity (CRO) is a common and serious sequel of treatments of craniopharyngiomas. The few therapeutic approaches that have been tested until now for the control of eating behaviour and weight have poor efficacy. Glucagon-like peptide-1 (GLP-1) analogues might be an option. Methods: This multicentre, randomised, double-blind superiority trial was conducted in France. Adults with CRO (BMI > 3...